



# 3<sup>rd</sup> Think Tank on Advancing Gastroesophageal Cancer Research

**November 14-15, 2019**

**Boston, MA**

## MEETING PROGRAM

---

PRESENTED BY

Adam Bass, MD & TargetCancer Foundation



TargetCancer  
Foundation

Boston College Club, 100 Federal Street, Boston, MA



# 3<sup>rd</sup> Think Tank on Advancing Gastroesophageal Cancer Research

---

Thank you for participating in the 2019 Think Tank on Advancing Gastroesophageal Cancer Research. We are grateful that you are joining us to share your insights and expertise, and we hope that the presentations and conversations over these two days will lead to new collaborations, define research priorities for the field, and ultimately accelerate the identification of new treatments.

TargetCancer Foundation is fortunate to collaborate with other advocacy organizations as we seek to support research and patients. Please join us in welcoming our partners at the Esophageal Cancer Action Network, the Esophageal Cancer Awareness Association, and the National Organization for Rare Disorders to the Think Tank.

In addition, the team from Count Me In will be present throughout the Think Tank to share information about the Esophageal and Stomach Cancer Project, a patient-partnered initiative that is generating critical data for the research community.

Finally, we would like to express our sincere thanks to our sponsors Leap Therapeutics and Taiho Oncology for their generous support of this meeting.



Jim Palma  
TargetCancer Foundation



Adam Bass, MD  
Dana-Farber Cancer Institute

# AGENDA - DAY 1

THURSDAY, NOVEMBER 14, 2019

---

- 8:00 AM**      **REGISTRATION, BREAKFAST, NETWORKING**
- 9:00 AM**      **WELCOME & INTRODUCTIONS**
- 9:15 AM**      **SESSION 1: CLINICAL & TRANSLATIONAL RESEARCH**
- Update on surgery for distal esophageal and GE junction cancer-current status and issues for progress**  
Scott Swanson, MD, *Brigham and Women's Hospital*
- Tethered capsule endomicroscopy for esophageal cancer screening**  
Guillermo Tearney, MD, PhD, *Massachusetts General Hospital*
- Integrating IO and XRT**  
Jonathan Schoenfeld, MD, MPH, *Dana-Farber Cancer Institute*
- 10:55 AM**     **MORNING STRETCH & COFFEE**
- 11:15 AM**     **SESSION 1 CONTINUED**
- Molecular heterogeneity and implications for systemic targeted therapies**  
Daniel Catenacci, MD, *University of Chicago*
- Emerging use of cfDNA in cancer monitoring**  
Viktor Adalsteinsson, PhD, *Broad Institute of MIT and Harvard*
- Determinants of immune resistance and response in gastrointestinal cancers**  
Marios Giannakis, MD, PhD, *Dana-Farber Cancer Institute*
- 12:55 PM**     **NETWORKING LUNCH**
- 1:50 PM**      **PATIENT-PARTNERED RESEARCH**
- Count Me In: Esophageal and Stomach Cancer Project**  
Sara Balch, *Count Me In, Broad Institute of MIT and Harvard*
- 2:45 PM**      **SESSION 2: ESOPHAGEAL SQUAMOUS CELL CARCINOMA**
- Model systems of and translation in esophageal squamous cell carcinoma**  
Anil Rustgi, MD, *Herbert Irving Comprehensive Cancer Center, Columbia University and New York-Presbyterian Hospital*
- Special and unique functions of cyclin D1 as a tumor promoter**  
J. Alan Diehl, PhD, *Case Western Reserve University*
- Evolution of SOX2 function in esophageal squamous cell carcinoma**  
Zhong Wu, MD, PhD, *Dana-Farber Cancer Institute*
- 4:25 PM**      **AFTERNOON STRETCH & COFFEE**
- 4:40 PM**      **ABSTRACT PRESENTATIONS**
- 5:20 PM**      **ESTABLISHING PRIORITIES FOR THE FUTURE OF GASTROESOPHAGEAL CANCER RESEARCH**
- GROUP DISCUSSION PART 1
- 6:00 PM**      **DINNER / POSTER SESSION / MINGLING**

# AGENDA - DAY 2

FRIDAY, NOVEMBER 15, 2019

---

**7:45 AM**      **REGISTRATION, BREAKFAST, NETWORKING**

**8:30 AM**      **WELCOME**

**8:40 AM**      **SESSION 3: GASTROESOPHAGEAL ADENOCARCINOMA**

**Epidemiology and gastric cancer in different populations**

Constanza Camargo, PhD, *National Cancer Institute*

**Helicobacter pylori and gastric cancer in 2020 and beyond**

Richard Peek, Jr., MD, *Vanderbilt University Medical Center*

**Metaplasia and dysplasia in gastric cancer development**

Eunyoung Choi, PhD, *Vanderbilt University Medical Center*

**10:20 AM**      **MORNING STRETCH & COFFEE**

**10:40 AM**      **SESSION 3 CONTINUED**

**Genomics of esophageal cancer development**

Matthew Stachler, MD, PhD, *University of California, San Francisco*

**Epigenetic insights into origins and mechanisms of Barrett's esophagus**

Harshabad Singh, MBBS, *Dana-Farber Cancer Institute*

**11:45 AM**      **NETWORKING LUNCH**

**12:45 PM**      **ABSTRACT PRESENTATIONS**

**1:20 PM**      **SESSION 4: NEW TECHNOLOGIES & MODELING SYSTEMS**

**Organoid modeling of the tumor immune microenvironment**

JT Neal, PhD, *Broad Institute of MIT and Harvard*


**An integrative mouse model to study gastric premalignancy**

Nilay Sethi, MD, PhD, *Dana-Farber Cancer Institute*

**2:30 PM**      **ESTABLISHING PRIORITIES FOR THE FUTURE OF GASTROESOPHAGEAL CANCER RESEARCH**

GROUP DISCUSSION PART 2

**3:00 PM**      **CONCLUSION OF MEETING**



# ABSTRACTS

---

## THURSDAY, NOVEMBER 14

**Samuel Klempner, MD** Massachusetts General Hospital, Harvard Medical School

*DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): tumoral DKK1 expression as a predictor of response and survival*

**Steve Maron, MD** Memorial Sloan Kettering Cancer Center

*Uses and limitations of ctDNA in esophagogastric cancer*

## FRIDAY, NOVEMBER 15

**Chin Hur, MD, MPH** Columbia University Medical Center

*Gastric and esophageal cancer global burden: which immigrants should we consider screening in the US*

**Ankur Nagaraja, MD, PHD** Dana-Farber Cancer Institute

*Cyclin E1 amplification in the chromosomally unstable subtype of gastroesophageal adenocarcinoma*

# POSTERS

---

**Alyssa Damon & Shahrayz Shah** Count Me In, Broad Institute of MIT and Harvard

*Count Me In: Partnering directly with patients to accelerate cancer research*

**Monika Laszkowska, MD** New York Presbyterian- Columbia University Medical Center

*Racial and ethnic disparities in mortality from gastric and esophageal adenocarcinoma*

**Shuo Qie, MD, PhD** Case Western Reserve University

*Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma*

**Minkyong Song, MD, PhD** National Cancer Institute

*Elevated anti-Epstein Barr virus antibodies in EBV-associated gastric carcinoma*

**Haisheng Zhang, PhD** Dana-Farber Cancer Institute

*Studying the pathogenesis and targeted therapy in diffuse gastric cancer*



Improving patient outcomes, one leap at a time



Leap Therapeutics in Cambridge, MA is an oncology focused drug development company. Leap is developing DKN-01, a monoclonal antibody designed to target key cellular pathways that enable cancer to grow and proliferate, and the pathways that help the body's immune system to identify and treat cancer. DKN-01 has been used as a monotherapy and in combination with PD-1 or paclitaxel to treat esophageal cancer.

Visit us at: [leaptx.com](http://leaptx.com)

© 2019 Leap Therapeutics, Inc. All Rights Reserved

Caring for cancer differently...

## It's all in the delivery

Taiho Oncology, Inc., is focused on bringing novel technology to cornerstone chemotherapies for a wide range of tumor types—including colorectal cancer and a variety of solid tumors. By developing oral oncolytic therapies, we are aspiring to deliver more meaningful moments to patients, and to redefine the way the world treats cancer.

To learn more, please visit [www.TaihoOncology.com](http://www.TaihoOncology.com).



Introducing

 **TAIHO ONCOLOGY**  
Making the human connection

© TAIHO ONCOLOGY, INC. 04/2017 All rights reserved. TOI-PM-US-0076 v2

## Through multiple efforts, TargetCancer Foundation is driving the gastroesophageal cancer research field forward:

- A seven year commitment to funding innovative and impactful esophageal cancer research at the Bass Lab at the Dana-Farber Cancer Institute, focusing on genomic studies and the role of immunotherapy.
- Support for studies around a key immunotherapy clinical trial, which has led to an improved treatment opportunity for esophageal cancer patients.
- Hosting the annual Think Tank on Advancing Gastroesophageal Cancer Research, a unique scientific meeting that fosters collaboration and idea generation among leading clinicians, researchers, advocates and patients.
- Partnering with Count Me In at the Broad Institute of MIT and Harvard on the development of the Esophageal and Stomach Cancer Project, an initiative that partners with patients to generate critical research data.

## TargetCancer Foundation also supports other rare cancer programs:

- Nine years of funding for innovative, high-impact cholangiocarcinoma research focusing on the development of cell lines, mouse models, and genomic studies.
- Lowering barriers to clinical trials through direct patient guidance and molecular profiling awareness and access programs.
- Serving as a public voice to raise awareness of the challenges faced by the rare cancer patient and research community.
- Leading a nationwide coalition of advocacy foundations devoted to rare cancers.



**TargetCancer Foundation** promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer Foundation directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients.



# TargetCancer Foundation

For more information, visit  
[www.targetcancerfoundation.org](http://www.targetcancerfoundation.org)

One Broadway, 14th Floor  
Cambridge, MA 02142  
[info@targetcancerfoundation.org](mailto:info@targetcancerfoundation.org)  
617-765-4881

